Reducing hypoglycaemia with insulin analogues

International Journal of Obesity

Volumn 26, Issue , 2002, Pages S31-S36

  Heller, S ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Biphasic insulin aspart; Glycaemic control; Hypoglycaemia; Insulin analogues; Pre mixes; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; GLUCOSE; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG DEGRADATION; DRUG INDUCED DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FOOD; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0036733069     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802175     Document Type: Article

References (27)

1. Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications trial. Diabetes Care 1995; 18: 1415–1427.
2. Turner R, Cull C, Holman R et al. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomised, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 135–145.
3. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD. Incidence of severe hypoglycaemia requiring emergency treatment in Type 1 and Type 2 diabetes: a population-based study of health service resource use. Diabetic Med 2002; 19(Suppl 2): 12–13.
4. Diabetes Control and Complications Trial (DCCT) research Group. The absence of a glycaemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289–1298.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
6. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46: 271–286.
7. Hepburn DA, Patrick AW, Eadington DW et al. Unawareness of hypoglycaemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabetic Med 1990; 7: 711–717.
8. Muhlhauser I, Berger M, Sonnenberg GE et al. Incidence and management of severe hypoglycaemia in 434 patients with insulin-dependent diabetes mellitus. Diabetes Care 1985; 8: 268–273.
9. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycaemia in patients with type 1 (insulin-dependent) diabetes with impaired awareness of hypoglycaemia. Diabetes Care 1994; 17: 697–703.
10. Fanelli CG, Epifano L, Rambotti AM et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42: 1683–1689.
11. Cranston I, Lomas J, Maran A, Macdonald IA, Amiel SA. Restoration of hypoglycaemia unawareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344: 283–287.
12. Dagogo-Jack SE, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not counterregulation, in IDDM. Diabetes 1994; 43: 1426–1434.
13. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus — a genetically programmed failure of the beta cell to compensate for insulin resistance. New Engl J Med 1996; 334: 777–783.
14. Kruszynska YT, Home PD. Night-time metabolic changes in normal subjects in the absence of the dawn phenomenon. Diabet Metab 1988; 14: 437–442.
15. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 739–746.
16. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999–1005.
17. Home PD. Rapid-acting insulin secretagogues: a clinical need? Exp Clin Endocrinol Diabetes 1999; 107(Suppl 4): S115–S119.
18. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind crossover trial in type 1 diabetes. Diabetes Care 1999; 22: 801–805.
19. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 200l; 159: 483–488.
20. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized doubleblind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904–1909.
21. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583–588.
22. Home PD, Lindholm A, Riis A. Insulin aspart vs human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Med 2000; 17: 762–770.
23. Heller S, Colagiuri S, Vaaler S, Wolffenbuttel BHR, Koelendorf K, Friberg HH, Windfeld K, Sondergaard K, Lindholm A. Reduced hypoglycaemia with insulin aspart in Type 1 diabetic patients: a double-blind randomised crossover trial. Diabetes 2001; 50: A137.
24. Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamineretarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399–403.
25. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapidacting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612–1614.
26. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabetic Med 2002; 19: 393–399.
27. Boehm B, Home P, Kamp N, Lindholm A. Biphasic insulin aspart and biphasic human insulin compared in Type 2 diabetic subjects. Diabetologia 2001; 44(Suppl 1): A210.